Abstract:
Accurate identification of human papillomavirus (HPV)-types in cervical cancer tissue may be important for tailoring tests for primary
screening and types to be included in a vaccine. The aim of this study was to compare test-performance of a 45-type HPV
deoxyribonucleic acid (DNA)-test with a 9-type HPV messenger ribonucleic acid (mRNA)-test in cervical cancer tissues.
In a case-series design 188womenwith diagnosed cervical cancer during the period January 2008 to July 1, 2011 at theGynaecological
Oncology Unit, University of Pretoria, South Africa were recruited to the study. After cases with negative internal controls for DNA/mRNA
detection (n=18) and unconfirmed histology (n=3) of cervical cancer were excluded, 167 women remained eligible for analysis. We
compared 45 DNA-types detected through general primer (GP)5+/6+ polymerase chain reaction (PCR) and reverse line blot (RLB)
genotyping with a modified version of the mRNA test PreTect HPV-Proofer detecting 9 genotypes (16, 18, 31, 33, 35, 45, 51, 52, 58).
Histological types were 92.2% squamous cell carcinoma, 4.8% adenocarcinoma, and 3.0% adenosquamous carcinoma. Overall,
HPV was detected in 95.2% (159/167) of specimens. The DNA- and mRNA tests each rendered 153/167 (91.6%) HPV positive
results. When restricting the analysis to the 9 high-risk HPV-types included in the mRNA test, 91.6% (153/167) and 88.0% (147/167)
were positive by the mRNA- and DNA-tests (P=.28), respectively. After hierarchical categorization of 9 comparable types, we found
concordance in 66 of 67 specimens for HPV16, 25 of 27 specimens for HPV18, 19 of 21 specimens for HPV45, and only in 33 of
45 for HPV31, 33, 35, 51, 52, 58. The positivity rate for the HPV types 16, 18, and 45 and the positivity rate for HPV 16, 18, 45, 33 and
35 by both tests was 66% to 68% and 80% to 83%, respectively.
Overall and when considering established high-risk types, the mRNA test has at least as high detection rate as the DNA test. The
mRNA test can be an appropriate research tool to describe causative HPV-types in cervical cancer tissue for health care planning
purposes.
